Missions and objectives
What is the ETPN?
The ETP Nanomedicine (ETPN) is an initiative led by industry since 2005 and set up together with the European Commission, to address the application of nanotechnology in healthcare. The ETPN believes that involving industry will accelerate the development of promising ideas, and provide the effective and safe healthcare products that patients demand.
The ETPN is officially recognized as an ETP, a key element in the European innovation ecosystem and a main bridge between the community and the European Commission to implement Research FrameWork Programmes.
In 2015, the ETPN became an independent Association under the French law 1901, with its Secretariat in central Paris, in the campus of the ESPCI (Ecole Supérieure de Physique et Chimie Industrielle de la ville de Paris). The association gathers today more than 125 members from 25 different Member States, covering all stakeholders of Nanomedicine : academia, SMEs, industry, pubic agencies, representatives from national platforms, European Commission, etc.
The strategic research priorities of the ETP Nanomedicine represent the core fields of interest and activities of the members of the technology platform: Regenerative Medicine and Biomaterials, Nanotherapeutics (including drug delivery), Medical devices including Nanodiagnostics and Imaging.
The ETPN acts as:
Supporting public funding of the most promising R&D topics – “where Nanomedicine can bring something more” – through strategic inputs coming for all stakeholders, towards the E.C.
Detecting the best innovations in Nanomedicine and facilitate their access to the clinic through the Nanomedicine Translation Hub, a global set of premium services, free-of-charge for the beneficiaries.
- Establish a clear strategic vision in the area resulting in a Strategic Research Agenda
- Decrease fragmentation in nano-medical research
- Mobilise additional public and private investment
- Identify priority areas
- Boost innovation in nanobiotechnologies for medical use
- Nanotechnology-based diagnostics
- Medical imaging
- Targeted drug delivery nanosystems and drug-free nanotherapeutics
- Regenerative medicine
Make Nanomedicine happen in Europe!
Nanomedicine, the application of nanotechnology to health, raises high expectations for millions of patients for better, more efficient and affordable healthcare and has the potential of delivering promising solutions to many illnesses. From diagnosis to disease monitoring, going through surgery and chemotherapy or regenerative medicine, nanotechnologies virtually impact all fields of current medicine.
ETPN support to the research in nanomedicine acts for a better understanding of the functioning of the human body at molecular and nanometric level and it will thus give us the possibility to intervene better at pre-symptomatic, acute or chronic stage of illnesses, aiming for the final improvement of patients life. Industry has increasing interest in stepping into the area of nanomedicine and the expected market share of final products is growing. In addition to the improved quality of health care, the creation of new jobs can be expected. There again, ETPN strongly acts to make Europe a great place to develop business in Nanomedicine, offering a unique network of academic labs, hospitals and SMEs covering all the value chain of nanotechnologies applications to healthcare, as illustrated by the European Nanomedicine Map.
Dissemination of knowledge, regulatory and IPR issues, standardisation, ethical, safety, environmental and toxicity concerns as well as public perception in general and the input from other stakeholders like insurance companies or patient organisations play an important role.